Medscape

EML4-ALK as a Predictive Marker for Response to EGFR Therapy

Investigators at Massachusetts General Hospital in Boston conducted an analysis of the fusion oncogene EML4-ALK and the more well-studied epidermal growth factor receptor (EGFR) mutation among a group ...
Medindia

Kanazawa University research: Visualizing how cancer drugs reshape proteins linked to lung cancer

Researchers at Nano Life Science Institute (WPI-NanoLSI) and the Cancer Research Institute at Kanazawa University led have uncovered how targeted lung cancer drugs alter the shape and behavior of a ...
ascopubs.org

A novel RT-PCR approach to detecting EML4-ALK fusion genes in archival NSCLC tissue.

A Japanese nationwide network for the diagnosis of EML4-ALK-positive lung cancer: A joint study of ALCAS and NEJ004. Background: The echinoderm microtubule-associated protein-like 4–anaplastic ...
EurekAlert!

Not all ALK fusions act the same: Variants influence treatment success in lung cancer

About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until ...
ascopubs.org

EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients.

Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. Background: A subset of lung ...
EurekAlert!

Not all lung cancer patients who could benefit from crizotinib are identified by FDA-approved test

Break apart a couple worm-like chromosomes and they may reconnect with mismatched tips and tails – such is the case of the EML4-ALK fusion gene that creates 2-7 percent of lung cancers. Almost exactly ...
Nasdaq

Genprex signs two lung cancer research agreements

Genprex (GNPX) has entered into a Sponsored Research Agreement – SRA – with the University of Michigan Rogel Cancer Center to study TUSC2, the tumor suppressor gene used in Genprex’s lead drug ...
Business Wire

Clinical Utility of ALK Fusion Detection by Liquid Biopsy

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the publication of a paper in the journal Lung Cancer, titled "Clinical Utility of Next-Generation ...
MedPage Today

D. Ross Camidge, MD, PhD, on Brigatinib's Promise in ALK-Positive NSCLC

Brigatinib (Alunbrig) continued to prove its value as a promising first-line treatment for ALK-positive non-small cell lung cancer (NSCLC), according to a second interim analysis of the ALTA-1L trial.
Seeking Alpha

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference ...

AUSTIN, Texas, Oct. 28, 2025 /PRNewswire/ -- Genprex, Inc. (GNPX) ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for ...
Morningstar

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International ...

AUSTIN, Texas, Oct. 23, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients ...